Hillard M. Lazarus

51.9k total citations · 10 hit papers
545 papers, 25.8k citations indexed

About

Hillard M. Lazarus is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Hillard M. Lazarus has authored 545 papers receiving a total of 25.8k indexed citations (citations by other indexed papers that have themselves been cited), including 335 papers in Hematology, 163 papers in Oncology and 131 papers in Genetics. Recurrent topics in Hillard M. Lazarus's work include Hematopoietic Stem Cell Transplantation (212 papers), Acute Myeloid Leukemia Research (154 papers) and Acute Lymphoblastic Leukemia research (123 papers). Hillard M. Lazarus is often cited by papers focused on Hematopoietic Stem Cell Transplantation (212 papers), Acute Myeloid Leukemia Research (154 papers) and Acute Lymphoblastic Leukemia research (123 papers). Hillard M. Lazarus collaborates with scholars based in United States, United Kingdom and Canada. Hillard M. Lazarus's co-authors include Stanton L. Gerson, Martin S. Tallman, Mark R. Litzow, David I. Marks, Jacob M. Rowe, Brenda Cooper, Arnold I. Caplan, Mary M. Horowitz, Selina M. Luger and Omer N. Koç and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Hillard M. Lazarus

530 papers receiving 25.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer

1983 1.7k citations Hillard M. Lazarus et al. profile →
Defining the Intensity of Conditioning Regimens: Working Definitions

2009 1.1k citations Sergio Giralt, Hillard M. Lazarus et al. profile →
Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy

2000 887 citations Brenda Cooper, Hillard M. Lazarus et al. Journal of Clinical Oncology profile →
Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia

2004 783 citations Robert Peter Gale, Hillard M. Lazarus et al. profile →
Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors

2001 643 citations Hillard M. Lazarus, Mitchell S. Cairo et al. profile →
Anthracycline Dose Intensification in Acute Myeloid Leukemia

2009 639 citations Hugo F. Fernández, Zhuoxin Sun et al. profile →
Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients

2005 607 citations Hillard M. Lazarus, Richard T. Maziarz et al. profile →
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

2006 591 citations Adele K. Fielding, Susan Richards et al. Blood profile →
Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use.

1995 586 citations Hillard M. Lazarus et al. PubMed profile →
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

2007 537 citations Anthony H. Goldstone, Susan Richards et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hillard M. Lazarus United States	76	13.4k	7.0k	5.9k	5.6k	4.6k	545	25.8k
Gerhard Ehninger Germany	78	13.6k 1.0×	6.5k 0.9×	5.2k 0.9×	3.8k 0.7×	6.1k 1.3×	678	25.0k
Robert Peter Gale United States	78	14.5k 1.1×	5.6k 0.8×	5.6k 0.9×	3.9k 0.7×	3.7k 0.8×	609	24.0k
Barry E. Storer United States	85	16.5k 1.2×	8.4k 1.2×	3.5k 0.6×	5.3k 1.0×	2.4k 0.5×	429	28.2k
H. Joachim Deeg United States	94	23.2k 1.7×	7.1k 1.0×	6.4k 1.1×	5.6k 1.0×	3.7k 0.8×	669	31.0k
Gèrard Socié France	91	18.7k 1.4×	7.4k 1.1×	4.8k 0.8×	4.9k 0.9×	3.4k 0.7×	701	30.2k
Arnold Ganser Germany	78	13.9k 1.0×	4.6k 0.7×	6.6k 1.1×	3.8k 0.7×	9.6k 2.1×	752	27.1k
Sergio Giralt United States	86	21.4k 1.6×	10.0k 1.4×	5.0k 0.9×	4.9k 0.9×	5.6k 1.2×	856	30.2k
Andrea Bacigalupo Italy	83	18.3k 1.4×	6.7k 1.0×	6.8k 1.2×	3.5k 0.6×	2.5k 0.6×	592	26.3k
Jakob Passweg Switzerland	72	13.3k 1.0×	6.1k 0.9×	5.5k 0.9×	2.7k 0.5×	3.1k 0.7×	497	21.0k
Éliane Gluckman France	93	19.2k 1.4×	6.5k 0.9×	6.9k 1.2×	3.6k 0.7×	4.6k 1.0×	627	29.5k

Countries citing papers authored by Hillard M. Lazarus

Since Specialization

Citations

This map shows the geographic impact of Hillard M. Lazarus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hillard M. Lazarus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hillard M. Lazarus more than expected).

Fields of papers citing papers by Hillard M. Lazarus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hillard M. Lazarus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hillard M. Lazarus. The network helps show where Hillard M. Lazarus may publish in the future.

Co-authorship network of co-authors of Hillard M. Lazarus

This figure shows the co-authorship network connecting the top 25 collaborators of Hillard M. Lazarus. A scholar is included among the top collaborators of Hillard M. Lazarus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hillard M. Lazarus. Hillard M. Lazarus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lazarus, Hillard M. & Robert Peter Gale. (2024). Cytokine therapy of acute radiation syndrome. Best Practice & Research Clinical Haematology. 37(4). 101599–101599.

Kaplan, David R., et al.. (2024). Analyte heterogeneity analysis as a possible potency parameter for MSC. Best Practice & Research Clinical Haematology. 37(4). 101596–101596.

Jolles, Stephen, Sergio Giralt, Tessa Kerre, et al.. (2023). Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. Frontiers in Oncology. 13. 1098326–1098326. 10 indexed citations

Jaimovich, Gregorio, Hillard M. Lazarus, & Robert Peter Gale. (2023). Hematopoietic cell transplants in resource-poor countries: challenges and opportunities. Expert Review of Hematology. 16(3). 163–169.

Ganzel, Chezi, Zhuoxin Sun, Timour Baslan, et al.. (2022). Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leukemia Research. 123. 106971–106971. 5 indexed citations

Wiernik, Peter H., Zhuoxin Sun, Larry D. Cripe, et al.. (2021). Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. British Journal of Haematology. 194(2). 309–318. 6 indexed citations

Scott, Jeffrey F., Konstantin V. Grigoryan, John G. Muzic, et al.. (2020). Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. JAMA Dermatology. 156(6). 631–631. 11 indexed citations

Cairo, Mitchell S., Kenneth R. Cooke, Hillard M. Lazarus, & Nelson J. Chao. (2020). Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. British Journal of Haematology. 190(6). 822–836. 54 indexed citations

Sundaram, Suchitra, Benjamin Tomlinson, Richard J. Creger, et al.. (2017). Early Cardiovascular Toxicity with Treatment of Follicular Lymphoma Is Associated with Shorter Overall Survival. Blood. 130. 2776–2776. 2 indexed citations

10.

Ueda, Masumi, Melvin Berger, Robert Peter Gale, & Hillard M. Lazarus. (2017). Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Reviews. 32(2). 106–115. 46 indexed citations

11.

Hahn, Theresa, Philip L. McCarthy, Anna Hassebroek, et al.. (2013). Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors. Journal of Clinical Oncology. 31(19). 2437–2449. 175 indexed citations

12.

Nock, Nora L., Cynthia Owusu, Emily L. Kullman, et al.. (2013). A Community-Based Exercise and Support Group Program in African-American Breast Cancer Survivors (ABCs). PubMed. 1(1). 15–24. 15 indexed citations

13.

Wadhera, Rishi K., Robert A. Kyle, Dirk R. Larson, et al.. (2011). Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 118(11). 2985–2987. 29 indexed citations

14.

Luger, Selina M., Olle Ringdén, M-J Zhang, et al.. (2011). Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplantation. 47(2). 203–211. 194 indexed citations

15.

McClune, Brian, Daniel J. Weisdorf, Tanya L. Pedersen, et al.. (2010). Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome. Journal of Clinical Oncology. 28(11). 1878–1887. 338 indexed citations

16.

Cripe, Larry D., Hajime Uno, Elisabeth Paietta, et al.. (2010). Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 116(20). 4077–4085. 182 indexed citations

17.

Gale, Robert Peter & Hillard M. Lazarus. (2010). How Helpful Are Meta-Analyses in Determining the Best Therapy of Blood Diseases?. Acta Haematologica. 125(1-2). 91–101. 2 indexed citations

18.

Goldstone, Anthony H., Susan Richards, Hillard M. Lazarus, et al.. (2007). In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 111(4). 1827–1833. 537 indexed citations breakdown →

19.

Shahjahan, Munir, et al.. (2005). Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplantation. 36(6). 475–479. 28 indexed citations

20.

Buck, Georgina, Michael Richards, James Franklin, et al.. (2003). The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years.. Blood. 102(11). 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact